IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor
Open Access
- 12 March 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 5 (7) , 1045-1051
Abstract
Resistance in Gram-negative bacteria to β-lactam drugs is mediated primarily by the expression of β-lactamases and co-dosing of β-lactams with a β-lactamase inhibitor (BLI) is a clinically proven strategy to address resistance. New β-lactamases that are not impacted by existing BLIs are spreading and creating the need for development of novel broader spectrum BLIs. IID572 is a novel broad spectrum BLI of the diazabicyclooctane (DBO) class that is able to restore the antibacterial activity of piperacillin against piperacillin/tazobactam-resistant clinical isolates. IID572 is differentiated from other DBOs by its broad inhibition of β-lactamases, and the lack of intrinsic antibacterial activity.Keywords
This publication has 42 references indexed in Scilit:
- Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae – Identification of LYS228Bioorganic & Medicinal Chemistry Letters, 2018
- Carbapenemase-Producing Organisms: A Global ScourgeClinical Infectious Diseases, 2017
- Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolateJournal of Antimicrobial Chemotherapy, 2017
- In vitroactivity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infectionsJournal of Antimicrobial Chemotherapy, 2017
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.Clinical Infectious Diseases, 2016
- Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing IsolatesAntimicrobial Agents and Chemotherapy, 2016
- The β‐Lactams Strike Back: Ceftazidime‐AvibactamPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales dataThe Lancet Infectious Diseases, 2014
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor CombinationDrugs, 2013
- Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative BacteriaAnnual Review of Microbiology, 2011